COST-EFFECTIVENESS OF INTERFERON BETA-1B IN SLOWING MULTIPLE SCLEROSIS DISABILITY PROGRESSION First Estimates

Brown, Murray G.; Murray, T. J.; Sketris, Ingrid; Fisk, John D.; LeBlanc, John C.; Schwartz, Carolyn E.; Skedgel, Chris

doi:10.1017/s026646230010203x

Cited by 30 publications

(21 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Existing analyses have produced a range of cost-effectiveness estimates from in excess of £1 million per QALY gained to cost saving. [30][31][32] Significant flaws in the modelling of natural history, efficacy, discontinuation of therapy, mortality and the treatment of uncertainty mean that none of these estimates can be considered robust. 33 In general, those models which produced very high cost-effectiveness estimates tended to have shorter time horizons (less than 10 years) or assumed that all benefit ceased when the patient stopped therapy.…”

Section: Economic Evaluations Of Disease Modifying Treatments For Msmentioning

confidence: 99%

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis

Tappenden

Chilcott²,

Eggington³

et al. 2004

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

show abstract

Section: Economic Evaluations Of Disease Modifying Treatments For Msmentioning

confidence: 99%

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis

Tappenden

Chilcott²,

Eggington³

et al. 2004

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Because these medications offer only partial control of the disease, researchers have conducted studies to demonstrate the utility of some of these treatments in clinical practice using cost effectiveness analyses [7][8][9]. The significant expense, partial efficacy, side effects, and requirement for self-injection of these medications have made their effectiveness in clinical practice difficult for researchers to determine.…”

Section: Introductionmentioning

confidence: 99%

Quality of life for veterans with multiple sclerosis on disease-modifying agents: Relationship to disability

Guarnaccia¹,

Aslan²,

O’Connor³

et al. 2006

JRRD

View full text Add to dashboard Cite

Abstract-Our objective was to compare self-reported healthrelated quality of life (HRQOL) for U.S. veterans with multiple sclerosis (MS) on disease-modifying agents with provider reports of HRQOL from standard disability measures. We conducted a 3-year prospective observational study of 204 subjects who used interferon beta or glatiramer acetate and compared subjects' responses on the Veterans Short-Form 36 (VSF-36) (36-item short-form functional status assessment for veterans) with the Kurtzke Expanded Disability Status Scale (EDSS) and the Functional System (FS) scales, which are standard MS disability scales. EDSS and FS scores were significantly correlated with some VSF-36 domains (physical function [r = -0.57], role physical [r = -0.37], and physical component summary [r = -0.40]) and weakly correlated with other domains. HRQOL scores did not predict disability or compliance with therapy. We observed decrements in HRQOL at relatively low disability levels. HRQOL measures directly associated with physical function were correlated with standard MS disability scales. Researchers need to clarify the role of HRQOL in clinical outcomes assessment, as shown by the lack of outcome sensitivity and predictive value of the VSF-36.

show abstract

“…However, the study did not consider work absenteeism, lost productivity and patient dependence on care, or the long-term costs of care. 72 Another model analyzing costs for patients with RRMS that considered long-term savings found that treatment with SC IFNβ-1a was cost-effective 73 : treatment with IFNβ-1a in the United Kingdom was estimated to cost £453 per month over 10 years and £222 per month of disability prevented over 20 years. Data were not reported for other DMTs.…”

Section: Cost-utility and Cost-effectiveness Analyses Of Dmtsmentioning

confidence: 99%

Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies

Owens¹,

Olvey

Skrepnek

et al. 2013

JMCP

View full text Add to dashboard Cite

COST-EFFECTIVENESS OF INTERFERON BETA-1B IN SLOWING MULTIPLE SCLEROSIS DISABILITY PROGRESSION First Estimates

Cited by 30 publications

References 4 publications

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis

Quality of life for veterans with multiple sclerosis on disease-modifying agents: Relationship to disability

Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies

Contact Info

Product

Resources

About